Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting
Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…Abstract Number: 2521 • 2014 ACR/ARHP Annual Meeting
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Background/Purpose The GO-FORTH, phase 2/3 clinical trial was conducted to examine the efficacy and safety of Golimumab (GLM) plus MTX in Japanese patients (pts) with…Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…Abstract Number: 567 • 2014 ACR/ARHP Annual Meeting
Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata® Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab
Background/Purpose: Anti-TNF agents namely adalimumab (ADA), etanercept (ETA) and infliximab (INF) are approved for the treatment of signs and symptoms of ankylosing spondylitis. Their efficacy…Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting
Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting
Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting
Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…Abstract Number: 566 • 2014 ACR/ARHP Annual Meeting
Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Background/Purpose The impact of certolizumab pegol (CZP) on clinical and Magnetic Resonance Imaging outcomes in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS)…Abstract Number: 75 • 2014 ACR/ARHP Annual Meeting
Robust Identification of Anti-TNF Non-Responders in RA from Blood
Background/Purpose: The number of biologic therapies approved for use in treating rheumatoid arthritis (RA) has grown steadily over the past 15 years. While many patients…Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting
Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients
Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…Abstract Number: 1528 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
Background/Purpose: Novel, targeted small-molecular medications are needed in the treatment of rheumatoid arthritis (RA). MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK)…Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…Abstract Number: 2495 • 2014 ACR/ARHP Annual Meeting
Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials
Background/Purpose: To assess the impact of golimumab (GLM) on physical function and employability in patients with rheumatoid arthritis (RA) with various prior treatment histories, after…Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 29
- Next Page »